Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - karcinom, ledvična celica - proteinska kinaza inhibitorji - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.